USPTO has published Phosphagenics’ application for a Pharmaceutical Formulation patent which is intended to protect the use of TPM in a broad range of injectable formulations (Pub. No: 20190015329, Pub. Date: 17/01/19). This patent, along with a joint Phosphagenics-Terumo patent specifically for TPM/Propofol, was referred to by the company in a November 2017 update.
The TPM formulation is described as suitable for topical, enteral or parenteral administration, but is considered particularly suitable as an injectable formulation.
https://www.uspto.gov/
- Forums
- ASX - By Stock
- AVE
- Terumo and Propofol Injectable
Terumo and Propofol Injectable, page-118
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $3.137K | 1.148M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
68 | 104358077 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 25645581 | 11 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
68 | 104358077 | 0.002 |
19 | 73250508 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 25478912 | 10 |
0.004 | 23890201 | 19 |
0.005 | 34632738 | 17 |
0.006 | 19365067 | 10 |
0.007 | 9365221 | 8 |
Last trade - 15.17pm 03/07/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online